Reaching primary endpoint during the different treatment sequences
| Amantadine-placebo group | Placebo-amantadine group | Both groups | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ⩾1 point improvement during placebo treatment | ⩾1 point improvement during placebo treatment | ⩾1 point improvement during placebo treatment | ||||||||||||||||
| Yes | No | Total | Yes | No | Total | Yes | No | Total | ||||||||||
| Reaching the primary endpoint was defined as reduction of at least one point on the FSS. Amantadine-placebo group shows the changes in period 1 and 2 for the group of patients taking amantadine first, then placebo. Placebo-amantadine group: changes in period 1 and 2 for the patients taking placebo, followed by amantadine. Both groups: changes in period 1 and 2 combined for both treatment groups. | ||||||||||||||||||
| ⩾1 point improvement during amantadine treatment | ||||||||||||||||||
| Yes | 2 | 6 | 8 | 1 | 3 | 4 | 3 | 9 | 12 | |||||||||
| No | 5 | 23 | 28 | 11 | 23 | 34 | 16 | 46 | 62 | |||||||||
| Total | 7 | 29 | 36 | 12 | 26 | 38 | 19 | 55 | 74 | |||||||||